ALLO vs MS · rev $22.0K vs P/E 20, $344.27B cap
Allogene Therapeutics Inc (ALLO) versus Morgan Stanley (MS) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Ted Pick.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
MS does not have a complete income-statement cache yet.
ALLO currently screens at market cap $258.1M. MS currently screens at market cap $344.27B and trailing P/E 19.8.
Not investment advice. Open the ALLO and MS stock pages for the full models.
Not investment advice.